Modified Lipoprotein-Derived Lipid Particles Accumulate in Human Stenotic Aortic Valves

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lehti, Satu ^a   Käkelä, Reijo ^b   Hörkkö, Sohvi ^d,e   Kummu, Outi ^d,e   Helske Suihko, Satu ^a,c   Kupari, Markku ^c   Werkkala, Kalervo ^c   Kovanen, Petri T ^a   Öörni, Katariina ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOMYELIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANIMAL CELL; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OXIDATION; PARTICLE SIZE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN MODIFICATION;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; APOLIPOPROTEIN B-100; CHOLESTEROL; EPITOPES; FEMALE; HUMANS; LIPOPROTEINS; LYSOPHOSPHATIDYLCHOLINES; MALE; MASS SPECTROMETRY; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; PLAQUE, ATHEROSCLEROTIC; REFERENCE STANDARDS; ULTRACENTRIFUGATION;

EID: 84878773570     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065810     Document Type: Article

References (75)

1. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, et al. (2011) Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 124: 1783-1791.
2. Olsson M, Thyberg J, Nilsson J, (1999) Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19: 1218-1222.
3. Rajamannan NM, (2009) Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 29: 162-168.
4. Hansson GK, (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
5. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389-2397.
6. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, et al. (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359: 1343-1356.
7. Sacks MS, Yoganathan AP, (2007) Heart valve function: a biomechanical perspective. Philos Trans R Soc Lond B Biol Sci 362: 1369-1391.
8. Butcher JT, Simmons CA, Warnock JN, (2008) Mechanobiology of the aortic heart valve. J Heart Valve Dis 17: 62-73.
9. Stephens EH, Chu CK, Grande-Allen KJ, (2008) Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve. Acta Biomater 4: 1148-1160.
10. Kovanen PT, Pentikäinen MO, (1999) Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med 9: 86-91.
11. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G, (2002) The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 3: 3-9.
12. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, et al. (1996) Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16: 523-532.
13. Lommi JI, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Kupari M, et al. (2011) High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis 219: 538-544.
14. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L, et al. (1994) Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 23: 1162-1170.
15. Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, et al. (2004) Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44: 1859-1866.
16. Pentikäinen MO, Öörni K, Ala-Korpela M, Kovanen PT, (2000) Modified LDL- trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 247: 359-370.
17. Filip DA, Nistor A, Bulla A, Radu A, Lupu F, et al. (1987) Cellular events in the development of valvular atherosclerotic lesions induced by experimental hypercholesterolemia. Atherosclerosis 67: 199-214.
18. Zeng Z, Nievelstein-Post P, Yin Y, Jan KM, Frank JS, et al. (2007) Macromolecular transport in heart valves. III. Experiment and theory for the size distribution of extracellular liposomes in hyperlipidemic rabbits. Am J Physiol Heart Circ Physiol 292: H2687-2697.
19. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, et al. (2008) 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1-142.
20. Havel RJ, Eder HA, Bragdon JH, (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353.
21. Radding CM, Steinberg D, (1960) Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. J Clin Invest 39: 1560-1569.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
23. Li CM, Chung BH, Presley JB, Malek G, Zhang X, et al. (2005) Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci 46: 2576-2586.
24. Forte T, Nichols AV, (1972) Application of electron microscopy to the study of plasma lipoprotein structure. Adv Lipid Res 10: 1-41.
25. Hakala JK, Öörni K, Pentikäinen MO, Hurt-Camejo E, Kovanen PT, (2001) Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 21: 1053-1058.
26. Veneskoski M, Turunen SP, Kummu O, Nissinen A, Rannikko S, et al. (2011) Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Free Radic Biol Med 51: 834-843.
27. Turunen SP, Kummu O, Harila K, Veneskoski M, Soliymani R, et al. (2012) Recognition of Porphyromonas gingivalis gingipain epitopes by natural IgM binding to malondialdehyde modified low-density lipoprotein. PLoS One 7: e34910.
28. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
29. Haimi P, Uphoff A, Hermansson M, Somerharju P, (2006) Software tools for analysis of mass spectrometric lipidome data. Anal Chem 78: 8324-8331.
30. Rajamäki K, Lappalainen J, Öörni K, Välimäki E, Matikainen S, et al. (2010) Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5: e11765.
31. Basu SK, Goldstein JL, Anderson GW, Brown MS, (1976) Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A 73: 3178-3182.
32. Dylewski DP, Dapper CH, Valivullah HM, Deeney JT, Keenan TW, (1984) Morphological and biochemical characterization of possible intracellular precursors of milk lipid globules. Eur J Cell Biol 35: 99-111.
33. Dichlberger A, Cogburn LA, Nimpf J, Schneider WJ, (2007) Avian apolipoprotein A-V binds to LDL receptor gene family members. J Lipid Res 48: 1451-1456.
34. Dichlberger A, Schlager S, Lappalainen J, Käkelä R, Hattula K, et al. (2011) Lipid body formation during maturation of human mast cells. J Lipid Res 52: 2198-2208.
35. Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown MS, (1975) Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem 250: 8487-8495.
36. Guyton JR, Klemp KF, (1994) Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 14: 1305-1314.
37. Calder PC, (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83: 1505S-1519S.
38. Robenek H, Lorkowski S, Schnoor M, Troyer D, (2005) Spatial integration of TIP47 and adipophilin in macrophage lipid bodies. J Biol Chem 280: 5789-5794.
39. Esterbauer H, Gebicki J, Puhl H, Jurgens G, (1992) The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13: 341-390.
40. Williams KJ, Tabas I, (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15: 551-561.
41. Tabas I, Williams KJ, Boren J, (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116: 1832-1844.
42. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K, (2007) Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 27: 1159-1165.
43. Fogelstrand P, Boren J, (2012) Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis. Nutr Metab Cardiovasc Dis 22: 1-7.
44. Boren J, Gustafsson M, Skalen K, Flood C, Innerarity TL, (2000) Role of extracellular retention of low density lipoproteins in atherosclerosis. Curr Opin Lipidol 11: 451-456.
45. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, et al. (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417: 750-754.
46. O'Brien KD, Otto CM, Reichenbach DD, Alpers CE, Wight TN, (1995) Regional accumulation of proteoglycans in lesions of "degenerative" valvular aortic stenosis and their relationship to apolipoproteins. Circulation 92: I-612.
47. Öörni K, Pentikäinen MO, Annila A, Kovanen PT, (1997) Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J Biol Chem 272: 21303-21311.
48. Öörni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen PT, (2005) Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol 25: 1678-1683.
49. Plihtari R, Hurt-Camejo E, Öörni K, Kovanen PT, (2010) Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase. J Lipid Res 51: 1801-1809.
50. Pentikäinen MO, Öörni K, Kovanen PT, (2001) Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin. Arterioscler Thromb Vasc Biol 21: 1902-1908.
51. Pentikäinen MO, Lehtonen EM, Öörni K, Lusa S, Somerharju P, et al. (1997) Human arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles. J Biol Chem 272: 25283-25288.
52. Öörni K, Sneck M, Bromme D, Pentikäinen MO, Lindstedt KA, et al. (2004) Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 279: 34776-34784.
53. Öörni K, Pentikäinen MO, Ala-Korpela M, Kovanen PT, (2000) Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J Lipid Res 41: 1703-1714.
54. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M, (1986) Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 123: 109-125.
55. Nievelstein-Post P, Mottino G, Fogelman A, Frank J, (1994) An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb 14: 1151-1161.
56. Chao FF, Blanchette-Mackie EJ, Chen YJ, Dickens BF, Berlin E, et al. (1990) Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions. Am J Pathol 136: 169-179.
57. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, et al. (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28: 187-193.
58. Witztum JL, Steinberg D, (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792.
59. Hurt-Camejo E, Camejo G, Sartipy P, (2000) Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 11: 465-471.
60. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, et al. (2005) Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51: 2264-2273.
61. Kolasa-Trela RFK, Bazanek M, Grudzienń G, Sobczyk D, Sadowski J, et al. (2012) Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis. Clin Chem Lab Med 10: 1825-1831.
62. Kupreishvili K, Baidoshvili A, ter Weeme M, Huybregts MA, Krijnen PA, et al. (2011) Degeneration and atherosclerosis inducing increased deposition of type IIA secretory phospholipase A2, C-reactive protein and complement in aortic valves cause neutrophilic granulocyte influx. J Heart Valve Dis 20: 29-36.
63. Sartipy P, Johansen B, Camejo G, Rosengren B, Bondjers G, et al. (1996) Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J Biol Chem 271: 26307-26314.
64. Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, et al. (2003) Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 23: 1430-1436.
65. Edep ME, Shirani J, Wolf P, Brown DL, (2000) Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9: 281-286.
66. McMurray HF, Parthasarathy S, Steinberg D, (1993) Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 92: 1004-1008.
67. Quinn MT, Parthasarathy S, Steinberg D, (1988) Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 85: 2805-2809.
68. Goncalves I, Edsfeldt A, Ko NY, Grufman H, Berg K, et al. (2012) Evidence Supporting a Key Role of Lp-PLA2-Generated Lysophosphatidylcholine in Human Atherosclerotic Plaque Inflammation. Arterioscler Thromb Vasc Biol 32: 1505-1512.
69. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464: 1357-1361.
70. Vickers KC, Castro-Chavez F, Morrisett JD, (2010) Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells. Atherosclerosis 211: 122-129.
71. Miller JD, Weiss RM, Serrano KM, Brooks RM 2nd, Berry CJ, et al. (2009) Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 119: 2693-2701.
72. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, et al. (2002) Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105: 2660-2665.
73. Helske S, Otto CM, (2009) Lipid lowering in aortic stenosis: still some light at the end of the tunnel? Circulation 119: 2653-2655.
74. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD, (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90: 844-853.
75. Maskrey BH, Megson IL, Whitfield PD, Rossi AG, (2011) Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler Thromb Vasc Biol 31: 1001-1006.